Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

829
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

855
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
855
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

935
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

267
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
267
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

313
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
313

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Highly Sensitive SPR Biosensor for BCR-ABL Gene Sequence Detection Using a Novel Gold Nanoparticle-Enhanced Sandwich Assay Format.

Micromachines·2026
Same author

Ultrasensitive Impedimetric Electrochemical DNA Biosensor for Detection of Enterotoxigenic <i>Escherichia coli</i> (ETEC).

ACS omega·2026
Same author

A Proposed Algorithm for the Management of Patients with Cardiogenic Shock Based on Contemporary Knowledge and Gaps in Evidence.

Journal of cardiovascular development and disease·2025
Same author

Heart Failure Diagnosis and Severity Estimation enhanced by Generative Adversarial Network.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Prognosis and Risk Stratification of Patients with Advanced Heart Failure Followed-Up on an Outpatient Clinic.

Biomedicines·2025
Same author

A Non-Stenting Approach to Left Main Thrombus in an Oncology Patient with Acute Heart Failure: A Case Report.

The American journal of case reports·2025

Related Experiment Video

Updated: Jan 27, 2026

Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
05:58

Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes

Published on: March 22, 2022

4.5K

Point-of-Care Testing Devices for Heart Failure Analyzing Blood and Saliva Samples.

Evanthia E Tripoliti, Penelope Ioannidou, Petros Toumpaniaris

    IEEE Reviews in Biomedical Engineering
    |March 21, 2019
    PubMed
    Summary
    This summary is machine-generated.

    Point-of-care testing (POCT) devices offer rapid biomarker measurement for heart failure (HF) diagnosis and management. This review explores POCT innovations and their clinical implementation challenges.

    More Related Videos

    Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
    03:47

    Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

    Published on: July 12, 2024

    1.1K
    Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
    04:20

    Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

    Published on: October 1, 2019

    6.2K

    Related Experiment Videos

    Last Updated: Jan 27, 2026

    Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
    05:58

    Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes

    Published on: March 22, 2022

    4.5K
    Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
    03:47

    Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

    Published on: July 12, 2024

    1.1K
    Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
    04:20

    Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

    Published on: October 1, 2019

    6.2K

    Area of Science:

    • Cardiovascular Medicine
    • Biomarker Analysis
    • Medical Diagnostics

    Background:

    • Heart failure (HF) is a growing global cardiovascular crisis, increasing mortality and healthcare costs.
    • Accurate HF diagnosis and management are crucial, with biomarkers significantly improving prediction of adverse events.
    • Biomarker analysis at the point-of-care (POCT) offers rapid results, enhancing clinical decision-making.

    Purpose of the Study:

    • To review point-of-care testing (POCT) devices for measuring biomarkers in heart failure (HF) management.
    • To assess both commercially available and prototype POCT devices.
    • To discuss challenges and barriers to the clinical adoption of POCT for HF.

    Main Methods:

    • Literature review of POCT devices for HF biomarker measurement.
    • Inclusion of devices utilizing blood and saliva samples.
    • Analysis of technological advancements in microfluidics and nanotechnology for POCT.

    Main Results:

    • POCT devices leverage microfluidics and nanotechnology for rapid biomarker quantification.
    • Reviewed devices range from commercial products to developmental prototypes.
    • Both blood and saliva are explored as sample types for POCT analysis.

    Conclusions:

    • POCT devices show promise for improving HF diagnosis and management through rapid biomarker assessment.
    • Further research and development are needed to overcome implementation challenges and facilitate widespread clinical adoption.
    • Successful integration of POCT can reduce the burden of HF on patients and healthcare systems.